[ad_1]
Beware of recovery provisions.
Elanco Animal Health, issue of El Lilly last fall, announced the acquisition Friday of Aratana Therapeutics, a biotech focused on the development of drugs for dogs and cats, under the umbrella of A stock purchase agreement worth approximately $ 234 million, or $ 4.75 per share. Aratana shareholders can obtain additional payments based on sales objectives. The company's medications include treatments for osteoarthritis, lack of appetite, and pain relief after surgery.
…
[ad_2]
Source link